Cingulate Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Cingulate Inc. (CING) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $1.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-08-13
- Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2026-06-30 was $1.36M, a 9.13% increase year-over-year.
- Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2026-03-31 was $2.09M, a 110.95% increase year-over-year.
- Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2025-12-31 was $1.32M, a 1.39% increase year-over-year.
- Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for the quarter ending 2025-09-30 was $1.23M, a 32.99% decline year-over-year.
- Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $4.79M, a 0.35% decline from fiscal 2024.
- Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $4.80M, a 31.89% decline from fiscal 2023.
- Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was $7.05M, a 48.95% increase from fiscal 2022.
- Cingulate Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was $4.73M, a 563.21% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 3 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 3 month as first filed | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 6 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 6 month as first filed | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 9 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 9 month as first filed | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.36M 10-Q · filed 2026-08-13 | $3.45M 10-Q · filed 2026-08-13 | $4.77M derived: sum of 3 quarters · filed 2026-08-13 | $6.00M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $2.09M 10-Q · filed 2026-05-14 | $3.41M derived: sum of 2 quarters · filed 2026-05-14 | $4.64M derived: sum of 3 quarters · filed 2026-05-14 | $5.88M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.55M derived: sum of 2 quarters · filed 2026-03-18 | $3.80M derived: sum of 3 quarters · filed 2026-08-13 | $4.79M 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $1.23M 10-Q · filed 2025-11-13 | $2.47M derived: sum of 2 quarters · filed 2026-08-13 | $3.46M 10-Q · filed 2025-11-13 | $4.77M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $1.25M 10-Q · filed 2026-08-13 | $2.24M 10-Q · filed 2026-08-13 | $3.54M derived: sum of 3 quarters · filed 2026-08-13 | $5.37M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $989.99K 10-Q · filed 2026-05-14 | $2.29M derived: sum of 2 quarters · filed 2026-05-14 | $4.12M derived: sum of 3 quarters · filed 2026-05-14 | $5.02M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $3.13M derived: sum of 2 quarters · filed 2026-03-18 | $4.03M derived: sum of 3 quarters · filed 2026-03-18 | $4.80M 10-K · filed 2026-03-18 | |||
| 2024-09-30 | $1.83M 10-Q · filed 2025-11-13 | $2.73M derived: sum of 2 quarters · filed 2025-11-13 | $3.50M 10-Q · filed 2025-11-13 | $5.46M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $897.44K 10-Q · filed 2025-08-19 | $1.67M 10-Q · filed 2025-08-19 | $3.63M derived: sum of 3 quarters · filed 2025-08-19 | $5.85M derived: sum of 4 quarters · filed 2025-08-19 | |||
| 2024-03-31 | $770.44K 10-Q · filed 2025-05-08 | $2.73M derived: sum of 2 quarters · filed 2025-05-08 | $4.95M derived: sum of 3 quarters · filed 2025-05-08 | $6.74M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $4.18M derived: sum of 2 quarters · filed 2025-03-27 | $5.97M derived: sum of 3 quarters · filed 2025-03-27 | $7.05M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $2.22M 10-Q · filed 2024-11-07 | $4.00M derived: sum of 2 quarters · filed 2024-11-07 | $5.09M 10-Q · filed 2024-11-07 | $6.26M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | $1.79M 10-Q · filed 2024-08-13 | $1.78M 10-Q · filed 2023-08-14 | $2.88M 10-Q · filed 2024-08-13 | $2.87M 10-Q · filed 2023-08-14 | $4.04M derived: sum of 3 quarters · filed 2024-08-13 | $5.17M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $1.09M 10-Q · filed 2024-05-08 | $2.25M derived: sum of 2 quarters · filed 2024-05-08 | $3.38M derived: sum of 3 quarters · filed 2024-05-08 | $4.46M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.29M derived: sum of 2 quarters · filed 2024-04-01 | $3.37M derived: sum of 3 quarters · filed 2024-04-01 | $4.73M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $1.13M 10-Q · filed 2023-11-13 | $1.25M 10-Q · filed 2022-11-14 | $2.21M derived: sum of 2 quarters · filed 2023-11-13 | $3.57M 10-Q · filed 2023-11-13 | $3.69M 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | $1.08M 10-Q · filed 2023-08-14 | $2.44M 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | $1.36M 10-Q · filed 2023-05-10 | ||||||
| 2021-12-31 | $713.70K 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |